- Active, not recruiting
NCT01415882: Phase 2: Ixazomib Citrate in Relapsed Multiple Myeloma, Not Refractory to Bortezomib
Updated: Oct 4, 2022
NCT01415882: Phase 2: Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
NCT01415882: Phase 2: Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib
This phase II trial studies how well ixazomib citrate works in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) but is not resistant to bortezomib (refractory). Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Sponsor
Collaborator
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT01415882
Official Title: Phase 2 Trial of Ixazomib Combinations in Patients With Relapsed Multiple Myeloma
First Posted : August 12, 2011
Click here to see details on ClinicalTrials.gov
Drug: Cyclophosphamide
Biological: Daratumumab
Drug: Dexamethasone
Drug: Ixazomib Citrate
Other: Laboratory Biomarker Analysis